A new study from Pfizer shows only a slight difference in the numbers of adolescents who test positive for the coronavirus between those who are vaccinated and those who are not.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
If there’s no difference, and we are quite aware of the unwanted sid3 effects of the Pfizer shot, why put our children at risk?
Why make the irrational decision to make vaccines mandatory for the youngest?!
Once again – for profits!
Pfizer said the data will be used to buttress its upcoming application to the Food and Drug Administration for full approval of its two-shot vaccine regimen for the 12-15 population. The shot is currently allowed under an Emergency Use Authorization.
Headline is MISLEADING, I think deliberately written so at Pfizer's instance.
Trials have shown that Pfizer's Covid vaccine has been effective in adolescents over four months.
Four Months is not "Long Term." 20/30/40 years (or lifelong) is Long Term.https://t.co/DfhiepJ48n
— Karthik (@twittkart) November 23, 2021
“The study of 2,228 adolescents between the wages of 12 and 15 showed that in the group given the vaccine, none of the roughly 1,100 adolescents vaccinated tested positive for the virus.
The study also showed that 30 youths who were not vaccinated tested positive, for a rate of 2.7 percent.”
“As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine’s safety and effectiveness profile in adolescents. This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed,” said Albert Bourla, Chairman and Chief Executive Officer at Pfizer. “We look forward to sharing these data with the FDA and other regulators.”
“These are the first and only disclosed longer-term data demonstrating the safety and efficacy of a COVID-19 vaccine in individuals 12 through 15 years of age,” said Ugur Sahin, CEO, and co-founder of BioNTech.
“The growing body of data we have compiled from clinical trials and real-world surveillance to date strengthen the base of evidence supporting the strong efficacy and favorable safety profile of our COVID-19 vaccine across adolescent and adult populations,” he said.